• VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
Auteur:Vertongen, Pascale; Camby, Isabelle; Darro, Francis; Kiss, Robert; Robberecht, Patrick
Informations sur la publication:Neuropeptides, 30, 5, page (491-496)
Statut de publication:Publié, 1996-10
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adenylate Cyclase -- metabolism
Brain Neoplasms -- pathology
Cell Cycle -- drug effects
Cell Division -- drug effects
DNA Replication -- drug effects
DNA, Neoplasm -- biosynthesis
Enzyme Activation -- drug effects
Glioblastoma -- pathology
Growth Inhibitors -- pharmacology
Neoplasm Proteins -- drug effects
Neoplasm Proteins -- physiology
Neuropeptides -- pharmacology
Pituitary Adenylate Cyclase-Activating Polypeptide
Polymerase Chain Reaction
RNA, Messenger -- biosynthesis
Receptors, Vasoactive Intestinal Peptide -- drug effects
Receptors, Vasoactive Intestinal Peptide -- physiology
Receptors, Vasoactive Intestinal Peptide, Type II
Tumor Cells, Cultured -- drug effects
Vasoactive Intestinal Peptide -- pharmacology
Note générale:Comparative Study
Journal Article
Research Support, Non-U.S. Gov't